BI-1569912
- Generic Name
- BI-1569912
Boehringer Ingelheim's Iclepertin Fails to Meet Endpoints in Phase III Schizophrenia Trials
• Boehringer Ingelheim's iclepertin, a GlyT1 inhibitor, failed to demonstrate statistically significant benefits in improving cognitive function in schizophrenia patients.
• The Phase III CONNEX program, involving over 1,800 patients across 41 countries, did not meet primary or key secondary endpoints at six months.
• As a result of the disappointing outcomes, Boehringer Ingelheim has discontinued the CONNEX-X long-term extension trial.
• The company remains committed to developing solutions for serious mental illnesses, with over 20 investigative therapies in its pipeline.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath